Emerging retatrutide, a combined-action treatment targeting both GLP-1 and GIP receptors, is generating considerable interest within the healthcare community. Initial clinical trials have revealed impressive reductions in body mass and improvements in physiological markers for patients with overweight. Experts believe this novel approach could r… Read More